Iria Valiño Seoane-rekin lankidetzan egindako argitalpenak (10)

2020

  1. Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity

    Frontiers in Immunology, Vol. 11

  2. Vasoactive intestinal peptide axis is dysfunctional in patients with Graves’ disease

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. The anti-inflammatory mediator, vasoactive intestinal peptide, modulates the differentiation and function of Th subsets in rheumatoid arthritis

    Journal of Immunology Research, Vol. 2018

  2. Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis

    Scientific Reports, Vol. 8, Núm. 1

2016

  1. Clinical relevance of VPAC1 receptor expression in early arthritis: Association with IL-6 and disease activity

    PLoS ONE, Vol. 11, Núm. 2

  2. Healthy and Osteoarthritic Synovial Fibroblasts Produce a Disintegrin and Metalloproteinase with Thrombospondin Motifs 4, 5, 7, and 12: Induction by IL-1β and Fibronectin and Contribution to Cartilage Damage

    American Journal of Pathology, Vol. 186, Núm. 9, pp. 2449-2461

2015

  1. Biomarkers predicting a need for intensive treatment in patients with early arthritis

    Current Pharmaceutical Design, Vol. 21, Núm. 2, pp. 170-181

  2. Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity

    Journal of Molecular Neuroscience, Vol. 56, Núm. 3, pp. 577-584

2014

  1. Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis

    PLoS ONE, Vol. 9, Núm. 1

  2. VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction

    Journal of Molecular Neuroscience, Vol. 52, Núm. 1, pp. 10-17